Purdue and Akston Biosciences Sign Partnership Agreement for Dog Cancer Drug Development
Akston Biosciences Corporation, dedicated to accelerating the biologics revolution in Animal Health, and Purdue University, today announced a strategic partnership to co-develop an anti-cPD-L1 monoclonal antibody (mAb) immunotherapy to treat cancer in dogs. In the partnership, Akston has received an exclusive option to license the anti-cPD-L1 mAb and will serve as a Contract Development and Manufacturing Organization (CDMO) to further develop and produce the antibody at its facility in Beverly, Massachusetts.